FY2027 Earnings Estimate for SLDB Issued By HC Wainwright

Solid Biosciences Inc. (NASDAQ:SLDB - Free Report) - Equities researchers at HC Wainwright issued their FY2027 earnings per share (EPS) estimates for shares of Solid Biosciences in a report released on Monday, July 14th. HC Wainwright analyst A. He expects that the company will earn ($1.70) per share for the year. HC Wainwright has a "Buy" rating and a $20.00 price target on the stock. The consensus estimate for Solid Biosciences' current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for Solid Biosciences' FY2028 earnings at ($0.74) EPS and FY2029 earnings at $1.10 EPS.

Solid Biosciences (NASDAQ:SLDB - Get Free Report) last issued its quarterly earnings data on Thursday, May 15th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.06).

SLDB has been the subject of a number of other reports. Barclays decreased their price objective on Solid Biosciences from $15.00 to $10.00 and set an "overweight" rating for the company in a report on Friday, May 16th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $16.00 price target on shares of Solid Biosciences in a research report on Thursday, May 22nd. Piper Sandler lowered their price objective on shares of Solid Biosciences from $20.00 to $17.00 and set an "overweight" rating on the stock in a report on Friday, May 16th. JMP Securities reissued a "market outperform" rating and issued a $15.00 price objective on shares of Solid Biosciences in a research report on Friday, June 6th. Finally, Citigroup started coverage on shares of Solid Biosciences in a research report on Thursday, June 26th. They issued a "buy" rating and a $14.00 target price for the company. Ten analysts have rated the stock with a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $15.10.

Solid Biosciences Price Performance

SLDB stock traded up $0.37 during trading hours on Wednesday, reaching $5.95. 1,171,340 shares of the stock were exchanged, compared to its average volume of 1,207,969. The firm's 50-day moving average is $4.13 and its 200-day moving average is $3.98. Solid Biosciences has a 12 month low of $2.41 and a 12 month high of $10.37. The company has a market cap of $460.80 million, a price-to-earnings ratio of -1.99 and a beta of 2.34.

Institutional Trading of Solid Biosciences

A number of hedge funds have recently modified their holdings of the stock. CWM LLC raised its holdings in Solid Biosciences by 15,188.5% in the 1st quarter. CWM LLC now owns 7,950 shares of the company's stock valued at $29,000 after acquiring an additional 7,898 shares during the period. Corton Capital Inc. acquired a new position in shares of Solid Biosciences in the fourth quarter valued at approximately $41,000. Ground Swell Capital LLC bought a new position in shares of Solid Biosciences during the first quarter worth approximately $42,000. Invesco Ltd. acquired a new stake in Solid Biosciences during the 4th quarter worth approximately $49,000. Finally, Sei Investments Co. bought a new stake in Solid Biosciences in the 4th quarter valued at $52,000. Institutional investors and hedge funds own 81.46% of the company's stock.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.